VeriSilicon Partners With LVGL to Enable Advanced GPU Acceleration for Wearable Devices and Beyond
29.11.2024 01:00:00 CET | Business Wire | Press release
LVGL adds VeriSilicon’s 3D and VGLite 2.5D GPUs support to its library for a wide range of embedded applications
VeriSilicon (688521.SH) today announced a strategic partnership with LVGL, the leading open-source graphics library for embedded systems, to support VeriSilicon’s low-power 3D and VGLite 2.5D GPU technology within the LVGL library. This partnership aims to optimize performance and expand graphic processing capabilities for a wide range of embedded applications. As one of the first providers of 3D GPU technology for the LVGL ecosystem, VeriSilicon will contribute to advancing 3D rendering capabilities within the LVGL library.
LVGL is the most popular free and open-source embedded graphics library to create beautiful User Interfaces (UIs) for any Microcontroller Units (MCUs), Micro Processor Units (MPUs), or display type. By integrating VeriSilicon’s low-power and high-performance GPU solutions into LVGL’s graphics ecosystem, it offers developers the ability to rapidly deliver improved visual experiences, while maintaining power efficiency on compact, resource-constrained devices.
Actions Technology, a low-power AIoT fabless semiconductor company, is among the first to adopt this integrated solution in their smart watch System-on-Chips (SoCs). The company recognizes the potential of VeriSilicon’s low-power GPU technology, which, in conjunction with LVGL’s graphics library, will enhance the user experience of next-generation wearable devices.
Gabor Kiss-Vamosi, CEO of LVGL, said, “VeriSilicon’s VGLite 2.5D GPU technology has pioneered a new era in the embedded world, enabling complex vector graphics with exceptional speed and low power consumption. Now, we stand at the edge of a new revolution: the arrival of 3D GPUs to MCUs. This breakthrough will transform the embedded UI landscape, unlocking never-before-seen possibilities for user interfaces on small, resource-constrained, and battery-powered devices. At LVGL, we are excited to embrace this technology and harness its potential across a wide range of platforms. Our goal is to provide a great developer experience for VeriSilicon’s 3D GPUs, enabling seamless integration of 2D, 2.5D, and 3D content that will no doubt lead to some remarkable embedded applications.”
Tim Zhang, Wearable and Sensing Business Unit General Manager of Actions Technology, said, “LVGL’s flexible and powerful graphics solutions are essential to enhance the user interfaces of our wearable products. As the wearable industry embraces 3D graphics, the adoption of VeriSilicon’s powerful and energy-efficient technologies enables us to push the boundaries of innovation, delivering rich 3D graphics with low power consumption.”
“Wearable products are experiencing rapid growth, offering extended functionalities that go far beyond traditional watches. They have evolved into accessible information devices with integrated health monitoring features,” said Weijin Dai, Executive Vice President and General Manager of VeriSilicon’s IP Division. “With this growth, delivering a powerful user interface to effectively communicate information on small displays, while maintaining low power consumption, has become essential. At VeriSilicon, we work closely with our customers to integrate 3D GPU technology into their next-generation products. As a leading provider of wearable GPUs for both 2.5D and 3D applications, we collaborate with LVGL and partners like Actions to drive innovation and achieve this mission.”
About LVGL
LVGL Kft. is the creator of LVGL, the leading free and open-source graphics library for embedded systems, enabling high-quality UIs on any Microcontroller Unit (MCU), Micro Processor Unit (MPU), or display type. With a global community and industry partnerships, LVGL empowers developers to build visually rich, responsive, and efficient UIs for resource-constrained devices from wearables to industrial equipment. For more information, visit www.lvgl.io.
About Actions Technology
Actions Technology (688049.SH) is a leading low-power AIoT fabless semiconductor company in China. We excel in providing high-quality and low-latency wireless audio experiences while prioritizing power efficiency. Our core expertise includes high-performance audio ADC/DAC, voice pre-processing, audio encoding/decoding, and audio post-processing technologies, enabling a superior audio signal chain. Additionally, we specialize in low-latency wireless connectivity with Bluetooth RF, baseband, and protocol stack technologies at the core. For more information about Actions® high-quality, low-latency platform, visit www.actionstech.com.
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241128646659/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom